Tyra Biosciences
TYRA
113 hedge funds and large institutions have $676M invested in Tyra Biosciences in 2024 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 34 increasing their positions, 25 reducing their positions, and 18 closing their positions.
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
36% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 25
19% more funds holding
Funds holding: 95 → 113 (+18)
6.97% more ownership
Funds ownership: 89.1% → 96.07% (+7%)
36% less call options, than puts
Call options by funds: $53K | Put options by funds: $83K
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
39% less capital invested
Capital invested by funds: $1.11B → $676M (-$430M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$18.2M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$18M |
| 3 |
O
OrbiMed
New York
|
+$12.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$12.3M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$6.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$17.2M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$13M |
| 3 |
PA
Perceptive Advisors
New York
|
-$12M |
| 4 |
JP Morgan Chase
New York
|
-$5.04M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Mariner
Overland Park,
Kansas
| – | -$218K | -9,269 | Closed |
|
127
Acadian Asset Management
Boston,
Massachusetts
| – | -$19K | -848 | Closed |
|
|
NC
128
nVerses Capital
Wellington,
Florida
| – | -$9.4K | -400 | Closed |
|
|
AAP
129
Arax Advisory Partners
Denver,
Colorado
| – | -$165 | -7 | Closed |
|
|
CPA
130
Capital Performance Advisors
Walnut Creek,
California
| – | -$118 | -5 | Closed |
|
TYRA Hedge Fund Activity: Q4 2024 in Review
113 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q4 2024, worth a combined $676M — down 39% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TYRA positions and 18 closed out — a net gain of 18 holders — while 34 added to existing stakes and 25 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $18.2M. The largest seller was Frazier Life Sciences Management, exiting entirely with an estimated $17.2M sold.
- 113 institutional investors held Tyra Biosciences (TYRA) as of Q4 2024, up from 95 in Q3 2024.
- Funds reported $676M of Tyra Biosciences stock for Q4 2024, down 39% quarter-over-quarter.
- 36 funds opened new Tyra Biosciences positions in Q4 2024 and 18 closed out, a net change of +18 holders.
- The largest Tyra Biosciences buyer in Q4 2024 was Farallon Capital Management, an estimated $18.2M added.
- The largest Tyra Biosciences seller in Q4 2024 was Frazier Life Sciences Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q4 2024.